Compare NSIT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSIT | PHVS |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1996 | 2020 |
| Metric | NSIT | PHVS |
|---|---|---|
| Price | $116.69 | $33.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $116.25 | $41.82 |
| AVG Volume (30 Days) | 428.5K | ★ 566.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $8,247,180,000.00 | N/A |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $2.16 | N/A |
| P/E Ratio | $121.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $63.62 | $19.12 |
| 52 Week High | $148.36 | $36.60 |
| Indicator | NSIT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.47 | 50.71 |
| Support Level | $104.13 | $24.73 |
| Resistance Level | $123.69 | $36.60 |
| Average True Range (ATR) | 3.85 | 1.57 |
| MACD | -0.69 | -0.24 |
| Stochastic Oscillator | 51.52 | 24.17 |
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.